painless gastroscopy
Conditions
Interventions
Group R:Group R was intravenously injected with remifentanil 0.3 ug/kg, and then was treated with remimazolam at an initial dose of 5 mg followed by a supplementary dose of 2.5 mg
Group M:Group M was intravenously injected with remifentanil 0.3 ug/kg, and then was treated with mimazolam at an initial dose of 3-4 mg followed by a supplementary dose of 1 mg
Sponsors
Yantai Yuhuangding Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Scheduled to undergo a gastroscopy; 2. Aged 18~65 years.
Exclusion criteria
Exclusion criteria: 1. Required complex gastroscopy procedures (such as endoscopic submucosal dissection, etc.); 2. Patients with severe liver and kidney dysfunction; 3. Patients with psychiatric disorders , a long history of use of psychotropic drugs, and cognitive dysfunction; 4. History of drug and/or alcohol abuse; 5. Use of benzodiazepines and/or opioids for nearly three months; 6. Allergy or contraindication to benzodiazepines, opioids, flumazenil and their components.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| anterograde amnesia; | — |
Secondary
| Measure | Time frame |
|---|---|
| Conditions related to gastroscopy (the times of supplementary sedation,Dosage of remifentanil,the modified Observer's Assessment Alert/Sedation (mOAA/S) score after induction, sedation induction time, sedation duration, gastroscopy duration, time to eye opening and time to discharge from the postanesthesia care unit (PACU) );The incidences of adverse events (hypotension, bradycardia, hypoxemia, injection site pain, dizziness, abnormal gait, nausea and vomiting);The patient satisfaction toward anesthesia effect; | — |
Countries
China
Contacts
Public ContactAihua Jiang
The Affiliated Yantai Yuhuangding Hospital of Qingdao University
Outcome results
None listed